CLIMB BIO, INC. Operating Leases, Income Statement, Sublease Revenue
CLIMB BIO, INC. (CLYM) reported Operating Leases, Income Statement, Sublease Revenue of $33.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Income Statement › Other Income
us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue · last filed 2024-05-15
- CLIMB BIO, INC. operating leases, income statement, sublease revenue for the quarter ending 2024-03-31 was $33.00K.
- CLIMB BIO, INC. operating leases, income statement, sublease revenue for fiscal 2023 was $48.00K.
| Period end | Operating Leases, Income Statement, Sublease Revenue 3 month | Operating Leases, Income Statement, Sublease Revenue 12 month |
|---|---|---|
| 2024-03-31 | $33.00K 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $48.00K 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |